Plain-English translation of NCT06354218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an immune-boosting medication, combined with standard radiation therapy and chemotherapy for older adults (75 and above) with locally advanced esophageal squamous cell cancer that cannot be surgically removed. The study will enroll about 50 patients and track whether this medication helps improve the cancer's response to treatment while keeping side effects manageable. Researchers hope this combination may offer a better treatment option for older patients who cannot tolerate chemotherapy alone.
Esophageal cancer is difficult to treat, especially in older adults who may not be candidates for surgery or who struggle with the side effects of standard chemotherapy. This medication works by helping the immune system recognize and attack cancer cells, and researchers want to see if combining it with radiation and chemotherapy can improve outcomes without causing unacceptable harm.
You likely qualify if…
You likely don't qualify if…
You will receive the new immune medication intravenously (through an IV) once every 3 weeks, combined with radiation therapy and chemotherapy taken by mouth (Monday through Friday during radiation weeks). Before treatment begins, you'll undergo several tests including imaging scans, blood work, and heart tests to make sure you're healthy enough to participate. Throughout the study, doctors will monitor you closely for side effects and check how well the treatment is working using imaging scans and blood tests.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China